Shopping Cart
- Remove All
Your shopping cart is currently empty
MK-8745 is a potent and selective Aurora A inhibitor.

| Pack Size | Price | Availability | Quantity |
|---|---|---|---|
| 5 mg | $34 | In Stock | |
| 10 mg | $51 | In Stock | |
| 25 mg | $91 | In Stock | |
| 50 mg | $148 | In Stock | |
| 1 mL x 10 mM (in DMSO) | $38 | In Stock |
| Description | MK-8745 is a potent and selective Aurora A inhibitor. |
| Targets&IC50 | Aurora A:0.6 nM |
| In vivo | MK-8745 induces apoptosis in a p53-dependent manner across various cell lines in vitro. Exposure of p53 wild-type cells to MK-8745 leads to the induction of p53 phosphorylation (ser15) and an increase in p53 protein expression. This p53-dependent apoptotic effect of MK-8745 is further confirmed in HCT 116 p53 (-/-) cells transfected with wild-type p53. In non-Hodgkin's lymphoma cell lines, MK-8745 causes cell cycle arrest at the G2/M phase with the accumulation of tetraploid nuclei, followed by cell death. Treatment with MK-8745 induces p21 (waf1/cip1) and CycB1, indicating cell cycle arrest and an increased population of cells in the G2/M phase. Additionally, MK-8745 treatment leads to the rapid degradation of Aurora-A substrates (TACC3, Eg5, and TPX2) following the reduction of phospho-Aurora-A. |
| Molecular Weight | 431.91 |
| Formula | C20H19ClFN5OS |
| Cas No. | 885325-71-3 |
| Smiles | Fc1c(Cl)cccc1C(=O)N1CCN(Cc2cccc(Nc3nccs3)n2)CC1 |
| Relative Density. | 1.430 g/cm3 (Predicted) |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. | ||||||||||||||||||||||||||||||||||||||||
| Solubility Information | H2O: < 1 mg/mL (insoluble or slightly soluble) Ethanol: 1 mg/mL (2.32 mM), Sonication is recommended. DMSO: 55 mg/mL (127.34 mM), Sonication is recommended. | ||||||||||||||||||||||||||||||||||||||||
| In Vivo Formulation | 10% DMSO+40% PEG300+5% Tween 80+45% Saline: 2 mg/mL (4.63 mM), Sonication is recommended. Please add the solvents sequentially, clarifying the solution as much as possible before adding the next one. Dissolve by heating and/or sonication if necessary. Working solution is recommended to be prepared and used immediately. The formulation provided above is for reference purposes only. In vivo formulations may vary and should be modified based on specific experimental conditions. | ||||||||||||||||||||||||||||||||||||||||
Solution Preparation Table | |||||||||||||||||||||||||||||||||||||||||
Ethanol/DMSO
DMSO
| |||||||||||||||||||||||||||||||||||||||||

Copyright © 2015-2025 TargetMol Chemicals Inc. All Rights Reserved.